Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

Although 80% of rheumatologists surveyed by data and research firm Decision Resources Group prescribe Pfizer’s (NYSE: PFE) Xeljanz (tofacitinib) for rheumatoid arthritis, this is usually used in later lines of therapy.

Physicians most frequently cite limited formulary coverage and reimbursement restrictions as the reasons for not prescribing Xeljanz earlier on in treatment. A notable proportion of the physicians surveyed consider the safety profile of the drug to be inferior to the tumor necrosis factor-alpha inhibitors, or they are not convinced that Xeljanz has clinically meaningful effect on structural damage. The majority of physicians, however, perceive Xeljanz as being at least as effective as TNF-alpha inhibitors on signs and symptoms, as well as on remission.

Biologics facing a challenge